Payment overview · 2025
General Payments
$528.37
35 reported records · 9 companies
Healthcare provider profile · identity verified
Brian Joseph Cormier, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · ESCALON, CA · NPI 1407045586
Verified facts
What the public records show
CMS Open Payments records show Brian Joseph Cormier, PA received $528.37 in general payments during 2025 across 35 reported records.
GlaxoSmithKline, LLC. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $153.22 | 29.0% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.35 | 25.6% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $76.44 | 14.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.96 | 8.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.10 | 7.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.81 | 4.7% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.71 | 4.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.48 | 3.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.30 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $483.37 | 34 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.52 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $118.65 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.98 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $23.71 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 186 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
186 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
186 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 669 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 102 |
| Losartan Potassium | Losartan Potassium | 361 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 335 | 73 |
| Lisinopril | Lisinopril | 306 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 69 |
| Omeprazole | Omeprazole | 238 | 61 |
| Gabapentin | Gabapentin | 229 | 64 |
| Metformin Hcl | Metformin Hcl | 228 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 51 |
| Jardiance | Empagliflozin | 186 | 48 |
| Furosemide | Furosemide | 148 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 46 |
| Glimepiride | Glimepiride | 131 | 48 |
| Alendronate Sodium | Alendronate Sodium | 129 | 39 |
| Baclofen | Baclofen | 123 | 38 |
| Simvastatin | Simvastatin | 113 | 28 |
| Potassium Chloride | Potassium Chloride | 109 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 30 |
| Trazodone Hcl | Trazodone Hcl | 103 | 24 |
| Eliquis | Apixaban | 101 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 27 |
| Synjardy | Empagliflozin/Metformin Hcl | 92 | 21 |
| Clonidine Hcl | Clonidine Hcl | 90 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 22 |
| Alprazolam | Alprazolam | 87 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 41 |
| Montelukast Sodium | Montelukast Sodium | 82 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 16 |
| Sertraline Hcl | Sertraline Hcl | 73 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 30 |
| Finasteride | Finasteride | 65 | 19 |
| Ozempic | Semaglutide | 65 | 15 |
| Pregabalin | Pregabalin | 65 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 13 |
| Levetiracetam | Levetiracetam | 61 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 20 |
| Ezetimibe | Ezetimibe | 60 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 21 |
| Famotidine | Famotidine | 56 | 16 |
| Carvedilol | Carvedilol | 54 | 20 |
| Allopurinol | Allopurinol | 53 | 16 |
| Atenolol | Atenolol | 52 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 52 | 14 |
| Meloxicam | Meloxicam | 50 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 11 |
| Azithromycin | Azithromycin | 49 | 42 |
| Mupirocin | Mupirocin | 48 | 29 |
| Meclizine Hcl | Meclizine Hcl | 46 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | 11 |
| Farxiga | Dapagliflozin Propanediol | 43 | 11 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Lovastatin | Lovastatin | 42 | 12 |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 14 |
| Ibuprofen | Ibuprofen | 36 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Nystatin | Nystatin | 30 | 17 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Cefaclor | Cefaclor | 25 | 14 |
| Glipizide | Glipizide | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 18 |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Prednisone | Prednisone | 20 | 12 |
| Temazepam | Temazepam | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $528.37 · 35 records | GlaxoSmithKline, LLC. | AREXVY, ARISTADA, BREZTRI, JARDIANCE, Kerendia, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, PAXLOVID, REPATHA, SHINGRIX, TRELEGY ELLIPTA, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error